Cambridge Cognition (COG) Share Price, News & Analysis

Company Overview

Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB digital cognitive assessment platform for drug development by enabling pharmaceutical companies to take new therapeutics from preclinical consultancy to pivotal studies and approval, as well as supports sponsors to enhance recruitment, develop safe and effective treatments, and enhance research and development efficiency. It also provides CANTAB Connect Research, a proprietary platform that provides insights into behaviours, underlying brain circuits, and measurement of digital cognitive biomarkers; CANTAB Mobile, a touchscreen assessment of memory, mood, and functional status to detect the earliest signs of clinically relevant memory problems; CANTAB Insight to assess cognitive health; and CANTAB BrainHealth for assessing workplace wellbeing. In addition, the company offers electronic questionnaires and scales, a digital bespoke questionnaire; NeuroVocalix, a voice analysis platform to analyze voice to assess neurological change; cognition kit, a high frequency testing kit to detect changes over time and day-to-day cognition with short regular tests using patients' own devices. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: 27.30 to 42.53
• 52-Week Range: N/A
• Volume: 32,630 shs
• Average Volume: 46,772 shs
• Market Capitalization: £17.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

COG Stock Analysis - Frequently Asked Questions

How were Cambridge Cognition's earnings last quarter?

Cambridge Cognition Holdings Plc (LON:COG) announced its quarterly earnings results on Tuesday, September, 22nd. The company reported ($1.50) EPS for the quarter. Cambridge Cognition had a negative net margin of 10.07% and a negative trailing twelve-month return on equity of 74.36%.

How do I buy shares of Cambridge Cognition?

Shares of COG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Cambridge Cognition own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cambridge Cognition investors own include Interserve (IRV), Tullow Oil (TLW), AMC Entertainment (AMC), Antofagasta (ANTO), Aviva (AV), Alibaba Group (BABA) and B&M European Value Retail (BME).

Company Calendar

• Last Earnings: 9/22/2020
• Today: 1/18/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: LON:COG
• CUSIP: N/A
• CIK: N/A
• Web: www.cambridgecognition.com
• Phone: 44 1223 810 700
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-1,320,000.00
• Net Margins: -10.07%
• Pretax Margin: N/A
• Return on Equity: -74.36%
• Return on Assets: -0.30%

Debt

• Debt-to-Equity Ratio: 92.53
• Current Ratio: 0.65
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: £13.08 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 4.31
• Book Value: GBX 6 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 41,940,000
• Free Float: N/A
• Market Cap: £17.84 million
• Optionable: Not Optionable
• Beta: 0.72